Health Catalyst slips; Piper Sandler downgrades to 'neutral'
Shares of healthcare tech firm Health Catalyst HCAT.O down 3.7% at $3.37 premarket
Piper Sandler downgrades stock to "neutral" from "overweight"
Cuts target price to $4 from $8, implying a 14.3% premium from the stock's last close
Piper cites lack of organic growth drivers that can indicate revenue growth recovery and create shareholder value
Notes, the CY25 revenue "guide-down removes all organic growth from the outlook and HCAT now expects CY26 revenue to decline y/y"
HCAT cut its CY2025 revenue outlook to $310 million from its previous forecast of $335 million
Average rating of 12 analysts is "hold", with a median PT of $5 - data compiled by LSEG
As of last close, HCAT down nearly 51% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Nvidia Launches Ising Model Driving Quantum Sector Surge, QUBT vs IONQ, Which Is More Worth Investing In?

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

AST SpaceMobile Shares Plunge in Overnight Trading, What Happened? Will It Affect SpaceX?

Tradingkey








